• Altimmune drew $10 million in Tranche Three on October 27, 2026, under a $125 million loan agreement with Hercules Capital and other lenders.
• Meeting clinical and financial milestones extended the interest-only period and amortization date to June 1, 2028.
• The minimum cash covenant now requires qualified cash equal to at least 60% of outstanding Term Loan Advances principal.
• A 1% tranche facility charge was deducted from funding; the end-of-term charge remains 6.25% of amounts funded.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001326190-26-000060), on October 29, 2026, and is solely responsible for the information contained therein.